Skip to main content

Advertisement

SpringerLink
Log in

Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches

  • Review Article
  • Theme: Translational Modeling and Dose Selection: From Preclinical to Humans
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Physiologically based pharmacokinetic (PBPK) models are built using differential equations to describe the physiology/anatomy of different biological systems. Readily available in vitro and in vivo preclinical data can be incorporated into these models to not only estimate pharmacokinetic (PK) parameters and plasma concentration–time profiles, but also to gain mechanistic insight into compound properties. They provide a mechanistic framework to understand and extrapolate PK and dose across in vitro and in vivo systems and across different species, populations and disease states. Using small molecule and large molecule examples from the literature and our own company, we have shown how PBPK techniques can be utilised for human PK and dose prediction. Such approaches have the potential to increase efficiency, reduce the need for animal studies, replace clinical trials and increase PK understanding. Given the mechanistic nature of these models, the future use of PBPK modelling in drug discovery and development is promising, however some limitations need to be addressed to realise its application and utility more broadly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

REFERENCES

  1. Tanaka C, Kawai R, Rowland M. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos. 2000;28(5):582–9.

    PubMed  CAS  Google Scholar 

  2. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet. 2003;42(10):883–908.

    Article  PubMed  CAS  Google Scholar 

  3. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56.

    Article  PubMed  CAS  Google Scholar 

  4. Berezhkovskiy LM. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci. 2004;93(2):364–74.

    Article  PubMed  CAS  Google Scholar 

  5. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918–33.

    Article  PubMed  CAS  Google Scholar 

  6. Poulin P, Haddad S. Advancing prediction of tissue distribution and volume of distribution of highly lipophilic compounds from a simplified tissue-composition-based model as a mechanistic animal alternative method. J Pharm Sci. 2012;101(6):2250–61.

    Article  PubMed  CAS  Google Scholar 

  7. Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett. 2003;138(1–2):29–49.

    Article  PubMed  CAS  Google Scholar 

  8. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45(5):511–42.

    Article  PubMed  CAS  Google Scholar 

  9. Brightman FA, Leahy DE, Searle GE, Thomas S. Application of a generic physiologically-based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos. 2006;34(1):94–101.

    Article  PubMed  CAS  Google Scholar 

  10. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, et al. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2011;50(5):331–47.

    Article  PubMed  CAS  Google Scholar 

  11. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos. 2007;35(10):1766–80.

    Article  PubMed  Google Scholar 

  12. Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D. From preclinical to human–prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos. 2012;33(2):111–21.

    Article  PubMed  CAS  Google Scholar 

  13. Chen Y, Jin JY, Mukadam S, Malhi V, Kenny JR. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos. 2012;33(2):85–98.

    Article  PubMed  Google Scholar 

  14. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS PharmSci. 2004;6(1):E6.

    Article  PubMed  Google Scholar 

  15. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.

    Article  PubMed  CAS  Google Scholar 

  16. Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet. 2008;47(4):261–75.

    Article  PubMed  CAS  Google Scholar 

  17. Edginton AN, Theil FP, Schmitt W, Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4(9):1143–52.

    Article  PubMed  CAS  Google Scholar 

  18. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259–67.

    Article  PubMed  CAS  Google Scholar 

  19. Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther. 2012;91(3):542–9.

    Article  PubMed  CAS  Google Scholar 

  20. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice. Cancer Res. 1986;46(8):3969–78.

    PubMed  CAS  Google Scholar 

  21. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517–28.

    PubMed  CAS  Google Scholar 

  22. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2010;99(3):1582–600.

    Article  PubMed  CAS  Google Scholar 

  23. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67–86.

    Article  PubMed  CAS  Google Scholar 

  24. Chabot JR, Dettling DE, Jasper PJ, Gomes BC. Comprehensive mechanism-based antibody pharmacokinetic modeling. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:4318–23.

    PubMed  Google Scholar 

  25. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol. 2008;8(3):401–13.

    Article  PubMed  CAS  Google Scholar 

  26. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Heal. 1997;13(4):407–84.

    CAS  Google Scholar 

  27. Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, et al. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev. 2009;12(1):1–24.

    Article  PubMed  Google Scholar 

  28. Pang KS, Durk MR. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn. 2010;37(6):591–615.

    Article  PubMed  CAS  Google Scholar 

  29. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652–62.

    Article  PubMed  CAS  Google Scholar 

  30. Poirier A, Cascais AC, Funk C, Lave T. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009;6(11):1975–87.

    Article  PubMed  CAS  Google Scholar 

  31. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007–17.

    Article  PubMed  CAS  Google Scholar 

  32. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211–23.

    Article  PubMed  CAS  Google Scholar 

  33. Hallifax D, Foster JA, Houston JB. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res. 2010;27(10):2150–61.

    Article  PubMed  CAS  Google Scholar 

  34. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994;47(9):1469–79.

    Article  PubMed  CAS  Google Scholar 

  35. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007;6(2):140–8.

    Article  PubMed  CAS  Google Scholar 

  36. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 1997;73(2):147–71.

    Article  PubMed  CAS  Google Scholar 

  37. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27(11):1350–9.

    PubMed  CAS  Google Scholar 

  38. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica. 2006;36(7):567–80.

    Article  PubMed  CAS  Google Scholar 

  39. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci. 2011 May 3.

  40. Poulin P, Hop CE, Ho Q, Halladay JS, Haddad S, Kenny JR. Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci. 2012;101(11):4308–26.

    Article  PubMed  CAS  Google Scholar 

  41. Paine SW, Menochet K, Denton R, McGinnity DF, Riley RJ. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos. 2011;39(6):1008–13.

    Article  PubMed  CAS  Google Scholar 

  42. Mahmood I. Interspecies scaling of renally secreted drugs. Life Sci. 1998;63(26):2365–71.

    Article  PubMed  CAS  Google Scholar 

  43. Mahmood I, Sahajwalla C. Interspecies scaling of biliary excreted drugs. J Pharm Sci. 2002;91(8):1908–14.

    Article  PubMed  CAS  Google Scholar 

  44. Bi YA, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos. 2006;34(9):1658–65.

    Article  PubMed  CAS  Google Scholar 

  45. Abe K, Bridges AS, Brouwer KL. Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos. 2009;37(3):447–52.

    Article  PubMed  CAS  Google Scholar 

  46. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2008;22(2):457–67.

  47. Peyret T, Poulin P, Krishnan K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol. 2010;249(3):197–207.

    Article  PubMed  CAS  Google Scholar 

  48. Poulin P, Ekins S, Theil FP. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol. 2011;250(2):194–212.

    Article  PubMed  CAS  Google Scholar 

  49. Poulin P, Theil FP. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci. 2009;98(12):4941–61.

    Article  PubMed  CAS  Google Scholar 

  50. Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011 Mar 30.

  51. Graham H, Walker M, Jones O, Yates J, Galetin A, Aarons L. Comparison of in-vivo and in-silico methods used for prediction of tissue: plasma partition coefficients in rat. J Pharm Pharmacol. 2012;64(3):383–96.

    Article  PubMed  CAS  Google Scholar 

  52. Small H, Gardner I, Jones HM, Davis JD, Rowland M. Measurement of binding of basic drugs to acidic phospholipids using surface plasmon resonance and incorporation of the data into mechanistic tissue composition equations to predict steady-state volume of distribution. Drug Metab Dispos. 2011;39(10):1789–93.

    Article  PubMed  CAS  Google Scholar 

  53. An G, Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. AAPS J. 2012;14(2):352–64.

    Article  PubMed  CAS  Google Scholar 

  54. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119–25.

    Article  PubMed  CAS  Google Scholar 

  55. Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 2009;5(3):259–93.

    Article  PubMed  CAS  Google Scholar 

  56. Sugano K. Computational oral absorption simulation for low-solubility compounds. Chem Biodivers. 2009;6(11):2014–29.

    Article  PubMed  CAS  Google Scholar 

  57. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50 Suppl 1:S41–67.

    Article  PubMed  CAS  Google Scholar 

  58. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225–37.

    Article  PubMed  CAS  Google Scholar 

  59. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem. 2004;47(16):4022–31.

    Article  PubMed  CAS  Google Scholar 

  60. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59.

    Article  PubMed  CAS  Google Scholar 

  61. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68.

    Article  PubMed  CAS  Google Scholar 

  62. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.

    Article  PubMed  CAS  Google Scholar 

  63. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–8.

    Article  PubMed  CAS  Google Scholar 

  64. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.

    Article  PubMed  CAS  Google Scholar 

  65. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci. 2010;99(2):1028–45.

    PubMed  CAS  Google Scholar 

  66. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687–709.

    Article  PubMed  CAS  Google Scholar 

  67. Patlak CS, Goldstein DA, Hoffman JF. The flow of solute and solvent across a two-membrane system. J Theor Biol. 1963;5(3):426–42.

    Article  PubMed  CAS  Google Scholar 

  68. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74(1):163–219.

    Article  PubMed  CAS  Google Scholar 

  69. Ferl GZ, Wu AM, DiStefano 3rd JJ. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33(11):1640–52.

    Article  PubMed  Google Scholar 

  70. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352–4.

    Article  PubMed  CAS  Google Scholar 

  71. Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci. 2011. doi:10.1002/jps.22550.

  72. Bungay PJ, Tweedy S, Howe DC, Gibson KR, Jones HM, Mount NM. Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist. Drug Metab Dispos. 2011;39(8):1396–405.

    Article  PubMed  CAS  Google Scholar 

  73. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, et al. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos. 2011;39(3):383–93.

    Article  PubMed  CAS  Google Scholar 

  74. Allan G, Davis J, Dickins M, Gardner I, Jenkins T, Jones H, et al. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica. 2008;38(6):620–40.

    Article  PubMed  CAS  Google Scholar 

  75. Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet. 2008;47(11):743–52.

    Article  PubMed  Google Scholar 

  76. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189–206.

    Article  PubMed  CAS  Google Scholar 

  77. Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(1 Suppl):91S–108S.

    Article  PubMed  CAS  Google Scholar 

  78. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931–56.

    Article  PubMed  CAS  Google Scholar 

  79. Bouzom F, Walther B. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fundam Clin Pharmacol. 2008;22(6):579–87.

    Article  PubMed  CAS  Google Scholar 

  80. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013–34.

    Article  PubMed  CAS  Google Scholar 

  81. Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet. 2011;50(9):613–23.

    Article  PubMed  CAS  Google Scholar 

  82. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005;59(6):691–704.

    Article  PubMed  Google Scholar 

  83. Bjorkman S, Wada DR, Berling BM, Benoni G. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci. 2001;90(9):1226–41.

    Article  PubMed  CAS  Google Scholar 

  84. Plowchalk DR, Rowland Yeo K. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol. 2012;68(6):951–60.

    Article  PubMed  CAS  Google Scholar 

  85. Ghobadi C, Johnson TN, Aarabi M, Almond LM, Allabi AC, Rowland-Yeo K, et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet. 2011;50(12):809–22.

    Article  PubMed  CAS  Google Scholar 

  86. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4(2):261–74.

    Article  PubMed  Google Scholar 

  87. Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos. 2012;33(2):99–110.

    Article  PubMed  CAS  Google Scholar 

  88. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, et al. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica. 2012;42(1):94–106.

    Article  PubMed  CAS  Google Scholar 

  89. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010;106(3):195–209.

    Article  PubMed  CAS  Google Scholar 

  90. Stepensky D. Local versus systemic anti-tumour necrosis factor-alpha effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. Clin Pharmacokinet. 2012;51(7):443–55. doi:10.2165/11599970-000000000-00000.

    Article  PubMed  CAS  Google Scholar 

  91. Pejovic M, Stankovic A, Mitrovic DR. Determination of the apparent synovial permeability in the knee joint of patients suffering from osteoarthritis and rheumatoid arthritis. Br J Rheumatol. 1995;34(6):520–4.

    Article  PubMed  CAS  Google Scholar 

  92. Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, et al. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care. 2004;27(5):1176–81.

    Article  PubMed  CAS  Google Scholar 

  93. Comper WD, Haraldsson B, Deen WM. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol. 2008;19(3):427–32.

    Article  PubMed  Google Scholar 

  94. Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 1994;46(3):847–54.

    Article  PubMed  CAS  Google Scholar 

  95. Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford A, et al. A novel relay method for determining low-clearance values. Drug Metab Dispos. 2012;40(9):1860–5. doi:10.1124/dmd.112.046425.

    Article  PubMed  CAS  Google Scholar 

  96. Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, et al. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab Dispos. 2012;40(6):1085–92.

    Article  PubMed  CAS  Google Scholar 

  97. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53–75.

    Article  PubMed  CAS  Google Scholar 

  98. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401–31.

    Article  PubMed  Google Scholar 

  99. Hopkins JC, Leipold RJ. On the dangers of adjusting the parameters values of mechanism-based mathematical models. J Theor Biol. 1996;183(4):417–27.

    Article  PubMed  CAS  Google Scholar 

  100. Heiskanen T, Kairemo K. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Curr Pharm Des. 2009;15(9):988–1007.

    Article  PubMed  CAS  Google Scholar 

  101. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol. 2009;182(12):7663–71.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

The authors would like to acknowledge the contribution of all colleagues in Pfizer Worldwide Research and Development that were involved in the projects described in this manuscript.

Author information

Authors and Affiliations

  1. Systems Modelling and Simulation Group, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide R&D, 35 Cambridgepark Drive, Cambridge, Massachusetts, 02140, USA

    Hannah M. Jones & Kapil Mayawala

  2. 4009 Sylvia Daoust, Québec City, Québec, Canada, G1X 0A6

    Patrick Poulin

Authors
  1. Hannah M. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kapil Mayawala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Poulin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah M. Jones.

Additional information

Guest Editors: Peter Bonate and Jenny Chien

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, H.M., Mayawala, K. & Poulin, P. Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches. AAPS J 15, 377–387 (2013). https://doi.org/10.1208/s12248-012-9446-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-012-9446-2

KEY WORDS

Search

Navigation